Breaking News

Drug Addiction-Pipeline Review H1 2018

ReportsWeb.com published “Drug Addiction” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Pharmaceutical and Healthcare disease pipeline guide Drug Addiction-Pipeline Review, H1 2018, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Get Free Sample Copy at http://www.reportsweb.com/inquiry&RW00011444210/sample

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Drug Addiction-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 8, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 14 and 6 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis..

 To buy Link@ http://www.reportsweb.com/buy&RW00011444210/buy/2000

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
-The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

For more information about this report http://www.reportsweb.com/drug-addiction-pipeline-review-h1-2018

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Company Profile

Addex Therapeutics Ltd
Aelis Farma SAS
Aphios Corp
BioCorRx Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Consegna Pharma Inc
Curemark LLC
Egalet Corp
Embera NeuroTherapeutics Inc
F. Hoffmann-La Roche Ltd
Heptares Therapeutics Ltd
Immunovaccine Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
Omeros Corp
Orexigen Therapeutics Inc
P2D Bioscience
Saniona AB
Stada Arzneimittel AG
Teva Pharmaceutical Industries Ltd
Vectura Group Plc

Email

Go to website